Because women with CRCs who had the BRAF V600E mutation had a worse prognosis than those with the BRAF wild-type (KRAS mutation and the wild type of both genes) gene (Figure 2A and 2B), we established the clinical features of the 115 women with metachronous or synchronous metastases, including ovarian metastases from CRC, according to the BRAF mutation status. The gene discussed is KRAS; the disease is colorectal carcinoma.